Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BTTXNASDAQ:PEARNYSE:UPHLNASDAQ:VSEE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTTXBetter Therapeutics$0.00$0.00$0.00▼$0.03$5K1.1918,768 shs105 shsPEARPear Therapeutics$0.00$0.03▼$6.74$4.17M0.457.75 million shs66.30 million shsUPHLUpHealth$0.00$0.00$0.00▼$0.55$4K0.858,180 shs159 shsVSEEVsee Health$1.13+0.9%$1.16$1.00▼$14.47$4.07MN/A1.04 million shs13,258 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTTXBetter Therapeutics0.00%0.00%-50.00%-50.00%-99.09%PEARPear Therapeutics0.00%0.00%0.00%0.00%0.00%UPHLUpHealth0.00%0.00%0.00%0.00%-99.96%VSEEVsee Health-0.02%-12.50%-7.82%-13.18%+111,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBTTXBetter TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APEARPear TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AUPHLUpHealthN/AN/AN/AN/AN/AN/AN/AN/AVSEEVsee Health1.3775 of 5 stars2.03.00.00.02.50.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTTXBetter Therapeutics 0.00N/AN/AN/APEARPear Therapeutics 0.00N/AN/AN/AUPHLUpHealth 0.00N/AN/AN/AVSEEVsee Health 4.00Strong Buy$5.00342.48% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTTXBetter TherapeuticsN/AN/AN/AN/AN/AN/APEARPear Therapeutics$12.69M0.00N/AN/A$0.22 per share0.00UPHLUpHealth$130M0.00N/AN/A$3.10 per share0.00VSEEVsee Health$6.38M0.64N/AN/A($3.40) per share-0.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTTXBetter Therapeutics-$39.76MN/A0.00∞N/AN/AN/AN/A6/4/2025 (Estimated)PEARPear Therapeutics-$75.49M-$0.22N/AN/AN/A-594.70%-217.85%-95.20%N/AUPHLUpHealth-$56.42M-$1.35N/A∞N/AN/AN/AN/AN/AVSEEVsee Health-$4.41MN/A0.00∞N/AN/A-182.59%-58.26%6/5/2025 (Estimated)Latest PEAR, VSEE, UPHL, and BTTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/5/2025N/AVSEEVsee Health-$0.09-$0.12-$0.03N/A$3.52 million$3.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBTTXBetter TherapeuticsN/AN/AN/AN/AN/APEARPear TherapeuticsN/AN/AN/AN/AN/AUPHLUpHealthN/AN/AN/AN/AN/AVSEEVsee HealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTTXBetter TherapeuticsN/AN/AN/APEARPear TherapeuticsN/A1.481.48UPHLUpHealthN/AN/AN/AVSEEVsee Health0.160.370.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTTXBetter Therapeutics34.00%PEARPear Therapeutics71.17%UPHLUpHealth56.10%VSEEVsee Health1.01%Insider OwnershipCompanyInsider OwnershipBTTXBetter Therapeutics51.40%PEARPear Therapeutics30.70%UPHLUpHealth34.24%VSEEVsee Health6.59%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTTXBetter Therapeutics4049.86 million24.23 millionOptionablePEARPear Therapeutics300142.74 million98.92 millionNot OptionableUPHLUpHealth1,75018.93 million12.45 millionNo DataVSEEVsee HealthN/A3.60 million3.37 millionN/APEAR, VSEE, UPHL, and BTTX HeadlinesRecent News About These CompaniesVSee Health faces Nasdaq compliance issue over late filingsJune 1 at 5:17 PM | investing.comVSee Health faces Nasdaq delisting over late filingJune 1 at 5:17 PM | uk.investing.comVSee Health, Inc. Receives Nasdaq Notice on Delayed Form 10-Q FilingMay 30, 2025 | businesswire.comVSee Health launches telehealth initiative in the PhilippinesMay 17, 2025 | investing.comVSee Health Launches AI-Powered Telehealth to Reduce Maternal Deaths in Remote PhilippinesMay 16, 2025 | businesswire.comVSee Health, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K FilingMay 12, 2025 | businesswire.comVSee Health Inc. Faces Nasdaq Delisting Over Late FilingMay 10, 2025 | investing.comVSee Health unveils AI-driven telenursing platformApril 18, 2025 | uk.investing.comVSee Unveils Advanced Telenursing Robotics Solution Targeting 3-5% Reduction in Hospital Nursing CostsApril 16, 2025 | finance.yahoo.comVSee Health Highlights: AI-Powered Telehealth Redefining the $787 Billion Digital Healthcare Market Featured Image featured image Admin MessageApril 2, 2025 | markets.businessinsider.comVSee Health Highlights: AI-Powered Telehealth Redefining the $787 Billion Digital Healthcare MarketApril 2, 2025 | prnewswire.comVSee Health issues letter to shareholders updating progressMarch 7, 2025 | markets.businessinsider.comVSee Issues Shareholder Letter Highlighting 2024 Achievements and Strong Growth Outlook for 2025March 6, 2025 | finance.yahoo.comVSee Health wins telehealth contract for mental health servicesMarch 6, 2025 | finance.yahoo.comVSee Health Secures $444K County Government Contract, Expanding Market Reach in Public Sector HealthcareMarch 5, 2025 | finance.yahoo.comVSee Health and LanguageLine Team Up to Boost Telehealth Adoption with Seamless, Scalable Multilingual CareFebruary 25, 2025 | finance.yahoo.comVSee Health and LanguageLine Team Up to Boost Telehealth Adoption with Seamless, Scalable Multilingual CareFebruary 25, 2025 | businesswire.comMaxim Group Initiates Coverage of VSee Health (VSEE) with Buy RecommendationFebruary 25, 2025 | msn.comVSee Health initiated with a Buy at MaximFebruary 24, 2025 | markets.businessinsider.comMaxim starts VSee Health at Buy, sees good momentum in new contractsFebruary 24, 2025 | markets.businessinsider.comMedia Sentiment Over TimePEAR, VSEE, UPHL, and BTTX Company DescriptionsBetter Therapeutics NASDAQ:BTTX$0.0001 0.00 (0.00%) As of 09:31 AM EasternBetter Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.Pear Therapeutics NASDAQ:PEARPear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.UpHealth NYSE:UPHL$0.0002 0.00 (0.00%) As of 11:01 AM EasternUpHealth, Inc. provides behavioral health solutions through the utilization of evidence-based treatments and services in the Americas. The company offers mental health and substance use disorder treatment services directly to consumers. It also provides detoxification, residential, partial hospitalization program, intensive outpatient program, outpatient services, and non-clinical recovery residence and supporting housing services. UpHealth, Inc. is headquartered in Delray Beach, Florida.Vsee Health NASDAQ:VSEE$1.13 +0.01 (+0.89%) As of 12:31 PM EasternVSee Health, Inc. is a no-code or low-code software as a service (SaaS) platform that enables clinicians and enterprises to create their telehealth workflows without programming. It engages in providing timely, quality healthcare to patients regardless of geographical barriers. The company is headquartered in Boca Raton, FL. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas TSMC Joins NVIDIA in UAE Push, Fueling Growth Outlook Constellation Energy and Meta Strike Nuclear Deal, Shares Whipsaw Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge Microsoft Stock Near Peak, Pullback Seen as Opportunity 3 Reasons Amazon Could Be the Best Tech Performer in June 3 Tech Stocks Insiders Are Buying: Speculative Plays for June Tesla’s Lofty 200 P/E Could Mean More Upside Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
